¿Qué es la injuria renal aguda?
Injuria renal aguda
Summary
Acute kidney injury (AKI) is an abrupt decline in kidney function, identified by a rise in serum creatinine and/or reduced urine output. It is a clinical syndrome rather than a single disease; common causes include hypovolemia, sepsis, nephrotoxins, intrinsic renal disease, and urinary obstruction. Prompt assessment should focus on severity, reversible causes, medication safety, fluid/electrolyte status, and indications for nephrology consultation or kidney replacement therapy. The following is a concise clinician-oriented framework based primarily on KDIGO and NICE guidance. [1,2]
Diagnostic definition and staging
KDIGO defines AKI as any of the following:
- Increase in serum creatinine by ≥0.3 mg/dL (≥26.5 µmol/L) within 48 hours
- Increase in serum creatinine to ≥1.5 times baseline within the preceding 7 days
- Urine output <0.5 mL/kg/hour for 6 hours
Staging is based on the worse of creatinine or urine-output criteria:
- Stage 1: creatinine 1.5–1.9 times baseline or increase ≥0.3 mg/dL; urine output <0.5 mL/kg/hour for 6–12 hours
- Stage 2: creatinine 2.0–2.9 times baseline; urine output <0.5 mL/kg/hour for ≥12 hours
- Stage 3: creatinine ≥3 times baseline, creatinine ≥4.0 mg/dL, initiation of kidney replacement therapy, or urine output <0.3 mL/kg/hour for 24 hours or anuria for ≥12 hours [1]
Serum creatinine may lag behind the actual decline in filtration, and oliguria is not required for diagnosis. Establish the baseline creatinine and trend, rather than relying on a single value.
Initial evaluation
Assess urgently for:
- Hemodynamic and volume status: blood pressure, perfusion, orthostasis, mucous membranes, weight change, edema, pulmonary congestion, and fluid balance.
- Potential causes:
- Prerenal/functional: gastrointestinal losses, poor intake, hemorrhage, sepsis, heart failure, cirrhosis.
- Intrinsic renal: acute tubular injury, glomerulonephritis, acute interstitial nephritis, vascular disease.
- Postrenal: bladder outlet obstruction, stones, malignancy, retroperitoneal disease.
- Medication and exposure history: NSAIDs, ACE inhibitors/ARBs, diuretics, aminoglycosides, vancomycin, iodinated contrast, proton-pump inhibitors, antibiotics, herbal products, and recent chemotherapy.
- Laboratory testing: repeat creatinine and electrolytes; bicarbonate, potassium, urea, CBC, glucose, and urinalysis with microscopy. Urine sediment findings such as casts, dysmorphic red cells, or significant proteinuria may suggest intrinsic renal disease.
- Imaging: renal and bladder ultrasound when obstruction is possible, the cause is unclear, or AKI does not rapidly improve. NICE recommends prompt ultrasound when obstruction is suspected and urgent imaging when pyonephrosis is a concern. [2]
Fractional excretion indices can be misleading, particularly with diuretic therapy, sepsis, chronic kidney disease, or mixed etiologies; they should not replace clinical assessment.
Management principles
- Treat the cause promptly: control sepsis, stop bleeding, relieve obstruction, and treat glomerulonephritis or interstitial nephritis when suspected.
- If hypovolemia is present, use isotonic crystalloid with frequent reassessment. Avoid reflexive fluid administration in patients with heart failure, cirrhosis, pulmonary edema, or other evidence of congestion.
- Avoid hypotension and maintain adequate renal perfusion; vasopressors may be required in vasodilatory shock after appropriate volume assessment.
- Review and adjust all medications according to current renal function. Temporarily withholding nephrotoxic or hemodynamically compromising agents may be appropriate, but ACE inhibitors/ARBs should not be permanently discontinued solely because AKI occurred; the indication and recovery should be reassessed.
- Dose-adjust renally cleared drugs and monitor potassium, bicarbonate, fluid balance, and urine output.
- Loop diuretics should not be used to “treat” AKI or accelerate renal recovery; they may be used for clinically significant volume overload.
- Do not use low-dose dopamine for renal protection. KDIGO recommends avoiding pharmacologic interventions that lack proven benefit and minimizing additional nephrotoxic exposure. [1]
Indications for urgent nephrology review or kidney replacement therapy
Urgent specialist assessment is warranted for:
- Refractory hyperkalemia
- Severe metabolic acidosis not responding to medical treatment
- Pulmonary edema or refractory fluid overload
- Uremic complications, such as encephalopathy, pericarditis, or clinically significant bleeding
- Persistent or worsening stage 2–3 AKI
- Suspected glomerulonephritis, vasculitis, acute interstitial nephritis, or thrombotic microangiopathy
- Unclear etiology, especially with active urinary sediment
- Suspected urinary obstruction not promptly relieved
The decision to initiate dialysis should be based on the overall clinical context and complications, not on an isolated creatinine or urea value. [1,2]
Follow-up
Patients should be reassessed after the acute episode for recovery of creatinine and urine output, blood pressure, proteinuria, and residual chronic kidney disease. AKI is associated with increased subsequent risk of chronic kidney disease, so incomplete recovery or persistent albuminuria merits ongoing kidney-function monitoring. [1]
Fuentes
- https://kdigo.org/wp-content/uploads/2016/10/KDIGO-2012-AKI-Guideline-English.pdf
- https://kdigo.org/guidelines/acute-kidney-injury/
- https://kdigo.org/wp-content/uploads/2026/03/KDIGO-2026-AKI-AKD-Guideline-Public-Review-Draft-March-2026.pdf
- https://kdigo.org/wp-content/uploads/2023/10/KDIGO-AKI-Guideline_Scope-of-Work_25Oct2023_Final.pdf
- https://www.nice.org.uk/guidance/ng148
- https://www.nice.org.uk/guidance/ng148/chapter/Recommendations
- https://labmed.org.uk/static/67773610-ec05-451a-868393085b96a0ac/NG148-Acute-kidney-injury.pdf
- https://pmc.ncbi.nlm.nih.gov/articles/PMC3877708/
- https://pmc.ncbi.nlm.nih.gov/articles/PMC12784442/table/TAB1/
- https://pmc.ncbi.nlm.nih.gov/articles/PMC12964832/table/Tab1/
- https://pubmed.ncbi.nlm.nih.gov/39115567/
- https://pubmed.ncbi.nlm.nih.gov/31909927/
- https://kdigo.org/wp-content/uploads/2017/04/KDIGO-AKI-Guideline_Cass-2014.pdf
- https://www.ncbi.nlm.nih.gov/books/NBK552160/bin/niceng148_pathway1.pdf
- https://kdigo.org/wp-content/uploads/2016/10/Master_KDIGO-2012-AKI-Guideline.pptx
Respuesta generada por inteligencia artificial a partir de las fuentes citadas. Verifica las fuentes antes de aplicarla.